Anti-Epileptic Drugs for Pediatrics Market to Surpass US$ 1,520.5 Million Threshold by 2025 globally, with North America positioned as the Growth Engine - Coherent Market Insights

Published On : Sep 26, 2017

The Global Anti-epileptic Drugs for Pediatrics Market by drug type (1st generation, 2nd generation, and 3rd generation) and region (North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa) was valued at US$ 671.9 million in 2016 and is projected to exhibit a CAGR of 7.9% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing incidence of epilepsy and associated co-morbidities are expected to be the major factors driving growth of the global anti-epileptic drugs for pediatrics market over the foreseeable future.

Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for chronic as well as refractory epilepsies. Improving the therapeutic efficacy and effectiveness while lowering the side effects and interactions for better effects in adjunctive therapies is the epicenter of research and development for new treatment options in terms of drugs. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders also, in 2016, Pfizer, Inc.’s Lyrica (pregabalin) cleared phase-3 clinical trials for prescription to pediatric patients. Furthermore, UCB Pharma Limited received the U.S. FDA-approval for Briviact, for the treatment of patients with partial onset seizures.

Browse 25 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on " Anti-Epileptic Drugs for Pediatrics Market by Drug Type (1st generation, 2nd generation, and 3rd generation), and Region (North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa) - Global Forecast to 2025"

To know the latest trends and insights prevalent in the Anti-Epileptic Drugs for Pediatrics Market, click the link below:

Manufacturers are focusing on research and development activities of pipeline products and study about the effectiveness of generic drugs to find a solution to the existing problems associated with the treatment of epilepsy in children. In 2017, second trial conducted in the FDA-sponsored EQUIGEN project confirmed that generic version of lamotrigine is bioequivalent to Lamictal, which is the brand-name form of the drug. Furthermore, Sunovion submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA), to use Aptiom (eslicarbazepine acetate) as monotherapy or adjunctive therapy in the treatment of partial-onset seizures (POS) for children of the age 4 years and below. Pfizer, Inc. has molecules NCT02072824, NCT01463306, and NCT01747915 for epilepsy in their pipeline. In 2017, Epygenix Therapeutics, Inc. received the U.S. FDA approval for orphan drug designation to EPX-100 and EPX-200 that are indicated for the treatment of patients suffering from Dravet syndrome, which is a catastrophic form of epilepsy.

Key Takeaways of the Anti-epileptic Drugs for Pediatrics Market:

  • The global anti-epileptic drugs for pediatrics market is expected to exhibit a CAGR of 9% over the forecast period (2016–2025), owing to the presence of high potential markets, especially in Asia Pacific, Latin America, the Middle East, and Africa
  • Robust developments in drug therapies, drugs showing potential in pipeline, and inclusion of generic versions of branded products in the market due to patent expiries are expected to drive the global anti-epileptic drugs for pediatrics market.
  • Some major players operating in the anti-epileptic drugs for pediatrics market include Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

Coherent Market Insights Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.